The Paris prosecutor’s office on Tuesday said that French actor Gerard Depardieu was in December last year charged with rape and sexual assault after authorities revived a 2018 investigation that was initially dropped.
Depardieu was not detained when he was handed the preliminary charges on Dec. 16 last year, the office said.
The prosecutor’s office addressed the charges after the case was leaked to the media.
Media reports have said that the charges relate to allegations made by an actress in her 20s that date back to 2018.
An initial inquiry against the star was dropped in 2019 because of lack of evidence, but was later revived.
French newspaper Le Parisien and broadcaster BFM TV said that the woman alleged that Depardieu assaulted her on Aug. 7 and Aug. 13, 2018, at his home in Paris.
The two met when Depardieu led a master class at her school, BFM TV reported.
The actress, who has not been named, first filed a complaint with details of alleged rape and assault in August 2018 in the southern French city of Aix-en-Provence.
The probe was taken over by Paris investigators, but was soon dropped.
Depardieu’s lawyer, Herve Temime, was not immediately available for comment, but he has previously said that the actor “absolutely denies any rape, any sexual assault, any crime.”
Depardieu, 72, is among France’s most well-known and controversial stars.
He has appeared in 200 films over six decades and is among a few French actors who have made a name for themselves in Hollywood.
He won a Golden Globe for his performance in Green Card, a 1990 English-language romantic comedy costarring Andie MacDowell.
His first big hit in France was Les Valseuses (Going Places), Bertrand Blier’s classic farce about two wandering thugs.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very